HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
1-[3-(Dimethylamino)propyl]-1-(4-fluorphenyl)-1,3-dihydroisobenzofuran-5-carbonitrilmonohydrobromid
CITALOPRAM HBR · ERDOSTEIN · Citalopram hydrogen bromide · Citalopram for system suitability CRS · Bonitrile HBr · Lu 10-171 HBr · Citalopran HBr · Citalopram-D4Br
![Molekülstruktur von 1-[3-(Dimethylamino)propyl]-1-(4-fluorphenyl)-1,3-dihydroisobenzofuran-5-carbonitrilmonohydrobromid](/img/chemical/77995.png)
Identifikatoren & physikalische Daten
| CAS No. | 59729-32-7 |
|---|---|
| Summenformel | C20H22BrFN2O |
| Durchschnittliche Molmasse | 405,3 g/mol |
| Monoisotopische Masse | 404,08995364 g/mol |
| SMILES | Br.CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21 |
| InChIKey | WIHMBLDNRMIGDW-UHFFFAOYSA-N |
| PubChem CID | 77995 |
| ChEMBL | CHEMBL1200781 |
| EC No. | 261-890-6 |
| DTXSID | DTXSID40872344 |
| Lokaler Name | 1-[3-(Dimethylamino)propyl]-1-(4-fluorphenyl)-1,3-dihydroisobenzofuran-5-carbonitrilmonohydrobromid |
Chemische & physikalische Eigenschaften
| Polarare Oberfläche (TPSA) | 36,3 |
|---|---|
| H-Brücken-Donoren | 1 |
| H-Brücken-Akzeptoren | 4 |
| Frei drehbare Bindungen | 5 |
| Schwere Atome | 25 |
| Formalladung | 0 |
| Komplexität | 466 |
| Human Drugs | FDA approved drugs -> Active ingredient |
| Schmelzpunkt | 182-188°C |
| Flammpunkt | 9℃ |
| Lagerbedingungen | 2-8°C |
| Löslichkeit | H2O: soluble (sparingly)Soluble to 50 mM in ethanol and to 10 mM in water |
| Aggregatzustand | powder |
| Farbe | White |
| Merck | 14,2318 |
| Stabilität | Stable. Incompatible with strong oxidizing agents. |
| Hauptanwendungen | clinical testing |
| InChI | 1S/C20H21FN2O.BrH/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H31H |
| InChIKey | WIHMBLDNRMIGDW-UHFFFAOYSA-N |
| SMILES | Br.CN(C)CCCC1(OCc2cc(ccc12)C#N)c3ccc(F)cc3 |
| CAS Datenbank | 59729-32-7(CAS DataBase Reference) |
Sicherheit & Vorschriften
| GHS-Einstufung | WarningH302 (96.5%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P270, P273, P301+P317, P330, P391, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 115 reports by companies from 15 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Regulatorische Informationen | Citalopram hydrobromide: Does not have an individual approval but may be used under an appropriate group standard |
| Hazard Classes and Categories | Acute Tox. 4 (96.5%) |
| Treatment | Establish and maintain an airway to ensure adequate ventilation and oxygenation. Gastric evacuation by lavage and use of activated charcoal should be considered. Careful observation and cardiac and vital sign monitoring are recommended, along with general symptomatic and supportive care. Due to the large volume of distribution of citalopram, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. There are no specific antidotes for Celexa. (L1712) |
| Expositionspfade | Rapidly and well absorbed from the GI tract. Peak plasma concentrations occur within 4 hours of a single orally administered dose. Bioavailability is 80% following oral administration. Food does not affect absorption. |
| Toxizitätsübersicht | The antidepressant, antiobsessive-compulsive, and antibulimic actions of citalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Citalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT<sub>1A</sub> autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs. |
| Signs and Symptoms | Symptoms most often accompanying citalopram overdose, alone or in combination with other drugs and/or alcohol, included dizziness, sweating, nausea, vomiting, tremor, somnolence, and sinus tachycardia. In more rare cases, observed symptoms included amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and very rare cases of torsade de pointes). Acute renal failure has been very rarely reported accompanying overdose. Withdrawal symptoms include flu-like symptoms, insomnia, nausea, imbalance, sensory changes and hyperactivity. |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)Citalopram hydrobromidevLess-DILI-concern7Adverse reactionsDOI:10.1016/j.drudis.2016.02.015 |
| Wassergefährdungsklasse (WGK) | 3 |
| UN-Transportnummer | 3249 |
| Zollcode | 29329990 |
| RTECS-Nr. | NP6313500 |
| R-Sätze (R) | 11-23/24/25-39/23/24/25-22 |
| Gefahrensymbole | F,T |
| Sicherheitshinweise (S) | 7-16-36/37-45-24/25 |
| Gefahrenklasse | 6.1(b)Acute Tox. 3 DermalAcute Tox. 3 InhalationAcute Tox. 3 OralFlam. Liq. 2STOT SE 1 |
| Verpackungsgruppe | III |
| Lagerklasse | 3 - Flammable liquids |
Anwendungen & Verwendung
Beschreibung
Citalopram (hydrobromide) (Item No. 23252) is an analytical reference material categorized as an antidepressant. This product is intended for use in analytical forensic applications. This product is also available as a general research tool .
Verwenden
Citalopram hydrobromide has been used:to examine its effects onsirtmRNA and mammalian sirtuins (SIRT) expression in miceto monitor body temperature and antidepressant-like behavioral responses in the forced swim test for ratsfor 5-hydroxytryptamine (5-HT) competition uptake assays